



TUBERCULOSIS PROJECT

CONTRIBUTE TO THE REDUCTION OF TUBERCULOSIS-RELATED MORBIDITY AND MORTALITY IN MADAGASCAR, IN LINE WITH THE “END TB” STRATEGY AND SUSTAINABLE DEVELOPMENT OBJECTIVES

CONTEXT

Madagascar, like many developing countries, suffers from the harmful effects of tuberculosis, causing early deaths and increasing poverty of the population. According to WHO estimates, the incidence of tuberculosis in Madagascar was 233 cases per 100,000 inhabitants in 2018. The average increase in cases over the last 10 years (2009-2018) was 5% per year for new cases and relapses, with 26.7% of deaths and 13.3% of cases lost.

Catholic Relief Services (CRS) was selected through the Global Fund’s Country Coordinating Mechanism (CCM/CCM), as Principal Recipient (PR) to manage the Madagascar Tuberculosis Program grant for the period January 1, 2021 - December 31, 2023.

GOALS

- Reduce the incidence rate of tuberculosis from 233 to 161 per 100,000 people
- Reduce the tuberculosis (TB) mortality rate from 48 to 30. per 100,000 people

BASIC FACTS OF PROJECT

TYPE OF PROJECT	Health
DONOR	15,094,285 USD from Global Fund
AREAS OF INTERVENTION	22 regions of Madagascar
SUB RECIPIENTS	<ul style="list-style-type: none"> • Programme National de Lutte contre la Tuberculose (PNLT) • SAF/FJKM • EKAR SANTE CES - Eglise Catholique Apostolique Romaine, • Commission Episcopale de la Santé
PERIOD	2021 - 2023

TARGET GROUPS/ PARTICIPANTS

Le groupe cible et les principaux bénéficiaires du programme comprennent les patients atteints de tuberculose, ainsi que les populations clés et/ou vulnérables identifiées par le plan stratégique national 2020-2024 (Personnes vivant avec VIH, personnes travaillant dans les sociétés minières, contacts, enfants, prisonniers et personnes atteintes de diabète).

STRATEGIES

- Accelerate early detection of tuberculosis with mandatory notification of all diagnostic cases.
- Ensure quality diagnosis of TB with capacity building of actors and increased use of more sensitive diagnostic tools.
- Ensure quality of care and treatment for all TB patients, including resistant TB and patient support.
- Ensure prevention, diagnosis, and treatment of TB index contacts, especially for children <5 years of age.
- Strengthen the management of HIV-TB.
- Extend prevention, particularly through contact and children under 5 years of age.

MAIN EXPECTED RESULTS

- ✓ Increase treatment coverage for new cases and relapses from 55% in 2018 to 90% in 2024.
- ✓ Treat 100% of tuberculosis patients and increase the treatment success rate to at least 90% for susceptible tuberculosis by 2024.
- ✓ Treat 100% of Multidrug- and rifampicin-resistant tuberculosis (MDR/RRTB) diagnosed patients and increase the treatment success rate to at least 75% for MDR-TB until 2024.
- ✓ Prevent tuberculosis for at least 90% of in-contact children and People Living with HIV after exclusion of tuberculosis by 2024.
- ✓ Provide HIV testing and ARV treatment to 100% of tuberculosis patients notified by 2021.
- ✓ Increase program management at all levels (monitoring and evaluation, collection and use of data for planning.)



GeneXpert® used at the Analakely Diagnostic and Treatment Center for tuberculosis screening.

Photo by To Filamatra/CRS